Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial

This publication has 30 references indexed in Scilit:

• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
  Annals of the Rheumatic Diseases, 2015
• Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis
  Seminars in Arthritis and Rheumatism, 2015
• 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
  Annals of the Rheumatic Diseases, 2013
• Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
  Annals of the Rheumatic Diseases, 2010
• Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
  Rheumatology, 2009
• B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
  Arthritis & Rheumatism, 2009
• Interstitial Lung Disease in Systemic Sclerosis
  American Journal of Respiratory and Critical Care Medicine, 2008
• Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis
  Molecular Immunology, 2004
• Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis
  Arthritis Care & Research, 2003
• The MOS 36-ltem Short-Form Health Survey (SF-36)
  Medical Care, 1992